Corona vaccine is coming: New strategy details known - subject explains side effects of vaccination

When will the new, promising vaccine from Biontech and Pfizer be delivered?

Health Minister Jens Spahn is certain: quickly.

Now the EU deal is ready.

• Health Minister

  Jens Spahn

  expects a

  delivery contract from

  the EU for a

  corona vaccine

  .

• The agent is being developed by the companies

  Biontech

  and

  Pfizer

  .

• There are still a few hurdles before it can be distributed to the population (update from November 11th, 3:31 p.m.).

• This news ticker is updated regularly.

Update from November 11th, 4:27 pm:

Chancellor

warns of excessive euphoria after the news about the new vaccine.

“We have to assume that the

, and it falls above all in a bad season,” she explains when the annual report of the “Wirtschaftsweise” is digitally presented.

The Spiegel reports.

The pandemic will keep us

busy

.

You have to continue to follow the rules.

New

announced.

According to research by

, planned vaccination centers will allow

the drug to be administered

to up to

day.

Around 100 physicians are required per center, according to the associations of statutory health insurance physicians.

Federal Health

(CDU)

wants to

talk to them about details on Friday,

continued.

Initial reactions to the new vaccine: These are the side effects

Update from November 11, 3:31 p.m.:

While the rest of the world is still longingly

waiting

for the

, some test subjects have

already had their first experiences

with the new serum from the pharmaceutical companies

.

The British

spoke to a few test subjects who received the vaccine in the test phase and

asked

them about the

.

According to the paper, a 44-year-old man from Texas initially describes the side effects as “a

”.

But the symptoms quickly subsided.

Two other test subjects are said to have reported side effects similar to those of a

: fever and headache and muscle pain.

After the second injection, these were more pronounced than after the first, but then disappeared again.

More than

part in the two companies' phase 3 study for their active ingredient.

Official green light for the EU deal with Biontech and Pfizer

Update from November 11th, 1:12 p.m.:

After the

and the pharmaceutical companies

and

negotiated a deal on Tuesday for the delivery of a total of 300 million doses of the new vaccine, the EU has now

confirmed this.

The EU now has

for the serum as soon as it receives approval.

When exactly this will be the case is still unclear.

No compulsory corona vaccination in Germany: Minister Karliczek wants "self-determined" decision

Update from November 11th, 11:28 am:

Given

Federal Research Minister

(CDU) made it clear that

should be

the increasing hope of a corona vaccination soon

.

Such an obligation is not provided, said Karliczek of the

.

With a view to possible concerns in the population, she emphasized that it is

important to keep the population

informed

* about the effectiveness of the vaccination and its risks.

"If there are positive results on the safety and effectiveness of vaccines, these should also be made known," said Karliczek.

This should help people to “make a self-determined

decision”.

In Germany, some feared that vaccination might become mandatory.

New corona vaccine: Biontech takes care of unjust distribution of the serum

Update from November 11, 10:25 a.m.:

Only a few days after the announcement of the first vaccine against the coronavirus, there were concerns about an

.

But the Mainz-based pharmaceutical company

 has countered fears that the

corona vaccine

it developed together with the US company

initially be distributed preferentially in the

.

"We have agreed with Pfizer that we will distribute the vaccine

," said Biontech CFO Sierk Poetting the

and the

.

His company "definitely does not want the batches to be unfairly inflated in individual regions," stressed Poetting.

That is why Biontech made it important that a large part of the vaccine

could be manufactured

.

"We will decide on the distribution together with Pfizer," emphasized the CFO.

Charité researchers on the new Biontech vaccine: "This is a turning point"

Update from November 11, 9.44 a.m.:

On Monday, the Mainz-based pharmaceutical company

and its US partner

announced that the first

doing

excellently in previous studies.

An effectiveness of up to 90 percent should be achieved.

Professor Leif Erik Sander, head of the Infection Immunology and Vaccine Research Research Group at the

, also felt

“joy and relief” at this news

.

He reveals that in an interview with

.

For a long time it was not clear whether a vaccine would even be found.

He did not expect the speed at which this had now happened.

“Work was carried out here at an almost unimaginable speed, and yet

” says the scientist.

However, he still urges caution.

At this point in time, the new developments

mean

in the fight against Covid-19.

“Because the vaccine is neither widely available nor has its

profile been adequately researched,” explains Sander in an interview.

But with this perspective one can

exercise

.

Because he believes that in the future, several vaccines could be successful and offer permanent protection.

New Biontech vaccine: EU delivery deal stands

Update from November 10th, 9:37 p.m.:

The negotiations of the

with the Mainz pharmaceutical company

and its US partner

*

are completed.

The contract is to be "signed in the coming days," said EU Health Commissioner Stella Kyriakides.

(CDU) now expects a swift approval process for the

.

The contract covers 200 million vaccine doses across Europe.

There is an option for another 100 million.

wants Germany to get 100 million doses of the serum.

According to the contract, Germany is entitled to 19 percent of the

total amount bought

by the

i.e. almost 56 million cans.

However, there is still a long way to go before individual citizens can be vaccinated:

Before the Biontech vaccine is distributed to the population, there are still a few hurdles

1st hurdle: production.

, but also other manufacturers, started production before approval.

For the production of a possible

, the Mainz-based company has

bought the production facility in Marburg

from the Swiss pharmaceutical company

.

300 employees work

there who are expected to produce

up to 250 million doses of the possible

in the first half of 2021

.

should be possible as soon as the production facility is fully functional.

2nd hurdle: distribution.

Production takes time - but the

of

those with

priority rights and the

itself also take time.

In a thesis paper, Matthias Schrappe, internist at the University of Cologne, assumes that it would take around

- i.e. four years - to vaccinate around 60 million people in Germany.

And only if

can be administered

.

Therefore the daily capacities have to be increased.

The Standing

(Stiko) at the

(RKI) expects that a comprehensive vaccination of the population against the

will take until 2022 - at

.

The federal states are setting up

for this purpose

.

Such a

in Munich

.

The

will - as soon as it is available - be delivered to the locations either by the Bundeswehr or by the companies themselves.

In addition,

vaccinate.

3rd hurdle: possible side effects.

It usually takes four to seven years for a new

approved.

There are accelerated approval procedures

for the

in Europe.

emphasizes that this would not reduce the requirements for potential side effects.

But Leif-Erik Sander, head of the Infection Immunology and Vaccine Research Research Group at the Charité in Berlin, admitted that

not too much can be said

about possible

.

According to the company, there were no

.

Sander points out, however, "that the observation period for relevant

still too short".

Biontech: It is still unclear whether vaccinated people can still transmit the virus

4th hurdle: Unclear effect.

It is also unclear whether

people who have been

can pass

on - which would be problematic especially for people who work in the health sector.

Clemens Wendtner, Head of Infectious Diseases at Munich Clinic Schwabing, assumes that the

- similar to the flu

- must be repeated regularly.

Sebastian Ulbert, immunologist at the Fraunhofer Institute in Leipzig, expects that seniors will

need

a

because of their weaker immune system

.

5th hurdle: acceptance.

The federal government emphasizes that there should be

.

However, the

has declined in recent years due to vocal campaigns by

and is currently less than 60 percent according to surveys.

This is not

to

develop

, which is why scientists are calling on politicians

to increase

to

with awareness-raising

.

"In the end, it needs a high level of acceptance," says

.

Biontech: EU secures 200 million doses of the vaccine

Update from November 10th, 4:08 p.m

.: Health Minister

hopes that

will receive

from Biontech and Pfizer

.

Two doses are required per vaccination.

The EU secured 200 million cans in a preliminary contract.

According to its own information, the Mainz-based pharmaceutical company

concluded

supply agreements

with its US partner

with several countries for a total of 570 million doses of its

for this year and next.

In addition, there are purchase options for a further 600 million cans,

on Tuesday.

All agreements are reportedly dependent on clinical success and approval.

In order to be able to cope with these quantities, the Mainz-based company had already

taken over

a production facility from the

in September

.

In total, Biontech has three production facilities in Germany.

In addition, there are at least four Pfizer plants in the USA.

Biontech: vaccine below usual market prices

Update from November 10th, 3 p.m

.:

wants to set the price for its corona vaccine below the "typical market prices".

Biontech manager Ryan Richardson told the

The pharmaceutical company wants to differentiate the pricing depending on the country and region in order to guarantee broad access worldwide.

Update from November 10th, 2:06 p.m

.: Research

has objected to concerns that a

* against the

* could

.

“We adhere to our high quality standards in the approval process,” she assured on Tuesday.

A corona vaccine must meet the same high standards as other vaccines.

“Therefore, approval this year would be a very, very, very enormous success,” said the minister.

It is

when the vaccine from the pharmaceutical

and

could come onto the market in Germany.

However, the EU has already negotiated a supply contract with the company

.

According to Karliczek, the German company Biontech was funded by the federal government with

for vaccine development.

An effective means could be the

that everyone was waiting for, said the CDU politician.

+

Education minister Anja Karliczek (CDU) emphasizes the high standards in vaccine development against the Sars-CoV-2 virus.

© Michael Kappeler / dpa

Coronavirus: Vaccine breakthrough in Germany - EU delivery deal stands

Origin notification dated November 10th

: Brussels -

The

has

fully negotiated

a

for the promising

the pharmaceutical

and

.

"The negotiations with the pharmaceutical industry have been concluded," the committee confirmed on Tuesday of the

in Brussels.

"The contract is dry." The

newspaper first reported on it.

Biontech and Pfizer get EU contract for corona vaccine

Federal Health

had already announced on Tuesday that the

sign a contract with Biontech and Pfizer "in a few days".

There are already preliminary contracts with Biontech and Pfizer, said Spahn on Tuesday in Berlin.

According to this, at least

secured for Europe.

He assumes that Germany

will receive

cans.

The Mainz-based company Biontech, led by Ugur Sahin, began developing a vaccine very early in 2020.

Now the market value of Biontech is skyrocketing.

+

Employees of the biotechnology company Biontech work in a laboratory.

© Biontech / dpa

Corona vaccine from Biontech / Pfizer: Different approval processes in the EU and the USA

The vaccine has not yet been officially approved.

BioNTech and Pfizer had stated they wanted early as next week in the

, the

request.

Spahn said that the approval procedures in the US and the EU are

.

But there are also opportunities for acceleration in Europe.

At the same time, guidelines on potential

of vaccines would not be lowered, stressed the minister.

The coronavirus laid bare the strains on our health systems and the limits of a model that values ​​wealth above wellbeing.

On Wednesday 11 November we present steps on how we can build a European #HealthUnion - a Union that is there to protect all.

Stay tuned!

pic.twitter.com/Y6zMYeDeq4

- European Commission 🇪🇺 (@EU_Commission) November 10, 2020

According to Spahn, the EU already has finished contracts with the pharmaceutical companies

and

, which are also working on corona vaccines.

A contract with the

has "basically" already been concluded.

(AFP / dpa / frs)

List of rubric lists: © Felix Kästle / dpa